An interventional study of RAMP Program in Chronic Pain, sponsored by Minneapolis Veterans Affairs Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Minneapolis Veterans Affairs Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.
Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 59th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 67 that started in 2026, is one of 803 with no phase, reaches primary completion later than 296 of the 347 other live ones, and was the 1,238th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–120
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18+ · Women only
University of Massachusetts, Boston · Sites in United States
Ages 65+
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,283 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 81 · Phase 2 112 · Phase 3 72 · Phase 4 50
First in 1992; this study’s year is marked. 67 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 60 across the 1,092 interventional studies, 100 across the 189 observational. Of the 848 that completed or were terminated, 386 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
209 of 1,283 have an industry lead sponsor. The 10 most frequent:
Minneapolis Veterans Affairs Medical Center is the lead sponsor of 40 studies on the registry; 4 are open to participants now.
Minneapolis Veterans Affairs Medical Center has 3 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
139 of the studies in Chronic Pain with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT06091202Phase 3Oregon Health and Science UniversityTele-Collaborative Outreach to Rural Patients With Chronic Pain | 2027-05-01 |
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT02979574Memorial Sloan Kettering Cancer CenterPEACE: Comparing Chronic Pain Treatment Options | 2026-11 |
| NCT03984565Staci Gruber, Ph.D.PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 1,283 studies in Chronic Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the RAMP mind-body program is to provide Veterans with information and tools that can help them manage their pain. The program explores the important connection between our bodies and minds, and how to use this special connection to manage pain more effectively.
Our long-term objective is to improve pain management and reduce opioid use among rural patients in the VA. To accomplish this, we will conduct a randomized clinical trial (RCT) to test the effectiveness of an innovative multi-component complementary and integrative intervention, Reaching Rural Veterans: Applying Mind-Body Skills for Pain Using a Whole Health Telehealth Intervention (RAMP) delivered via group telehealth, for improving rural Veterans' pain management, function, and wellbeing, within the VA healthcare system. This project addresses the significant challenge of implementing effective, non-opioid interventions for chronic pain management among rural Veterans, who experience a disproportionate share of the national pain burden, with more chronicity, opioid harms, comorbid mental health conditions and substance abuse, and are prescribed more opioids and have less access to evidence-based, chronic pain care that addresses their "whole-person" or biopsychosocial needs. The RAMP program strategically coalesces multiple evidence based CIH self-management strategies to address rural Veterans' biopsychosocial needs and overcome existing barriers to implementation. Comprised of pain education, mindfulness, pain specific exercises, and cognitive behavioral strategies, the program is cohesive and scalable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Behavioral: RAMP Program
RAMP is a 9-week program comprised of weekly online group sessions (90 minutes each) with pre-recorded expert-led education videos, mind-body skill training and practice, and facilitated discussions.
Pain interference
Measured using the Brief Pain Inventory (BPI) interference score. Minimum value: 0. Maximum value: 10. Higher scores indicate worse functioning.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Pain intensity
Measured using the Brief Pain Inventory (BPI) intensity score. Minimum value: 0. Maximum value: 10. Higher scores indicate more severe pain.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Pain impact
Measured using the Graded Chronic Pain Scale-Revised (GCPS-R), a six item scale developed to differentiate mild, bothersome, and high-impact chronic pain. Two questions to identify chronic pain and high impact chronic pain; frequency of pain during the prior 3 months and frequency of limitation in activities in the prior 3 months.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Quality of life
Measured using the World Health Organization (WHO) 2-item measure which measures quality of life and satisfaction with health on a 1 to 5 scale.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Quality of life
Measured using the Euro Quality of Life scale, a 5 section questionnaire to assess mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Physical functioning
Using the PROMIS Physical functioning 6-item short form v2.0 which measures difficulty doing household activities and agreement with statements on health limitations in physical activities on a 1 to 5 scale.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Sleep disturbance
Measured using PROMIS 6-item short form v1.0 which measures sleep quality on a 1 to 5 scale from very poor to very good in addition to agreement with statements on sleep quality on a 1 to 5 scale.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Sleep duration
Participants self-report their hours of sleep per night in the past month.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Fatigue
The PROMIS fatigue 4-item short form v1.0, which measures fatigue over the past 7 days.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Participation in Social Roles and Activities
Measured using the PROMIS 4-item short form v2.0 which measures frequency of trouble doing activities for leisure, work, or with family or friends on a 1 to 5 scale.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Anxiety
Anxiety will be measured using the Generalized Anxiety Disorder-2 survey (GAD-2) which includes 2 questions that are summed for a total score that can range from 0 to 6.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Depression
Depression will be measured using the Patient Health Questionnaire-2 (PHQ-2) which includes 2 questions that are summed for a total score that can range from 0 to 6.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Post Traumatic Stress Disorder (PTSD)
Measured using the Primary Care PTSD Screen for DSM-5, which asks whether the participant has had exposure to a traumatic event, and if yes, asks 5 follow-up yes/no question regarding experiences in the past month.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Overall improvement
Overall improvement will be assessed with the Patient Global Impression of Change (PGIC) which has participants rate their overall change from very much worse to very much improved on a 7-point scale.
Time frame: Average over 6 months of follow-up, with assessments at 10 weeks and 6 months.
Percentage of participants self-reporting opioid medication use
Participant self report of opioid medication use.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Substance use
Measured using the Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) survey. The TAPS is comprised of a 4-item screen for substance use.
Time frame: Average over 6 months of follow-up, with assessments at baseline, 10 weeks and 6 months.
Adverse events
Participant self-report of any new or worsening health issue while participating in the study. Participants will also be asked to report potential side effects by choosing from a list of known potential risks of exercise and mindfulness interventions.
Time frame: Average over 6 months of follow-up, with assessments at 10 weeks and 6 months.
Plan to share: Yes — The study data will be submitted to the National Institute of Mental Health (NIMH) Data Archive (NDA). Demographic and clinical outcome measures will be collected and shared using common data elements (CDEs ) from the NIH / HEAL CDE repository. Variable naming and permissible response values will be harmonized according to CDEs data dictionary specifications. Documentation to be made publicly available to the research community and will include: 1. The study protocol; 2. information sheet (provided per waiver of documentation of informed consent); 3. data collection forms/case report forms; 4. data dictionary.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Scientific data included in published manuscripts will be available at the time of publication; all other generated scientific data will be shared with the NDA repository no later than the end of the award.
Access criteria: Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication. The research project team and PRISM/Collaboratory Program Coordinating Center will work together in order to offer deidentified or limited data sets that will be available to the public. Where practicable, Limited Datasets (LDSs) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or reidentifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. No PHI or VA sensitive data will be shared, unless approved by VA Privacy Officers. Only authorized research personnel as approved by the ACOS in agreement with the MPIs, will have access to individually identifiable data.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 32 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Minneapolis Veterans Affairs Medical Center